SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:oru-53356"
 

Sökning: onr:"swepub:oai:DiVA.org:oru-53356" > Development of an i...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00007337naa a2200769 4500
001oai:DiVA.org:oru-53356
003SwePub
008161102s2018 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-533562 URI
0247 a https://doi.org/10.1136/gutjnl-2016-3126482 DOI
040 a (SwePub)oru
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Siegel, Corey A.u Dartmouth-Hitchcock Inflammatory Bowel Disease Center, Dartmouth-Hitchcock Medical Center, Lebanon NH, USA4 aut
2451 0a Development of an index to define overall disease severity in IBD
264 c 2016-10-25
264 1a London, United Kingdom :b BMJ Publishing Group Ltd,c 2018
338 a print2 rdacarrier
500 a Funding Agencies:AbbVie  Tillotts 
520 a Background and aim: Disease activity for Crohn's disease (CD) and UC is typically defined based on symptoms at a moment in time, and ignores the long-term burden of disease. The aims of this study were to select the attributes determining overall disease severity, to rank the importance of and to score these individual attributes for both CD and UC.Methods: Using a modified Delphi panel, 14 members of the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) selected the most important attributes related to IBD. Eighteen IOIBD members then completed a statistical exercise (conjoint analysis) to create a relative ranking of these attributes. Adjusted utilities were developed by creating proportions for each level within an attribute.Results: For CD, 15.8% of overall disease severity was attributed to the presence of mucosal lesions, 10.9% to history of a fistula, 9.7% to history of abscess and 7.4% to history of intestinal resection. For UC, 18.1% of overall disease severity was attributed to mucosal lesions, followed by 14.0% for impact on daily activities, 11.2% C reactive protein and 10.1% for prior experience with biologics. Overall disease severity indices were created on a 100-point scale by applying each attribute's average importance to the adjusted utilities.Conclusions: Based on specialist opinion, overall CD severity was associated more with intestinal damage, in contrast to overall UC disease severity, which was more dependent on symptoms and impact on daily life. Once validated, disease severity indices may provide a useful tool for consistent assessment of overall disease severity in patients with IBD.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Gastroenterologi0 (SwePub)302132 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Gastroenterology and Hepatology0 (SwePub)302132 hsv//eng
653 a Crohn's Disease
653 a IBD
653 a Ulcerative Colitis
7001 a Whitman, Cynthia B.u Department of Health Services, Cedars-Sinai Medical Center, Los Angeles CA, USA4 aut
7001 a Spiegel, Brennan M. R.u Department of Health Services, Cedars-Sinai Medical Center, Los Angeles CA, USA4 aut
7001 a Feagan, Brianu Department of Health Services, Cedars-Sinai Medical Center, Los Angeles California, USA4 aut
7001 a Sands, Bruceu Icahn School of Medicine at Mount Sinai, New York, USA4 aut
7001 a Loftus, Edward V.,c Jru Mayo Clinic, Rochester MN, USA4 aut
7001 a Panaccione, Remou University of Calgary, Calgary AB, Canada4 aut
7001 a D'Haens, Geertu Academic Medical Center, Amsterdam, Netherlands4 aut
7001 a Bernstein, Charles N.u University of Manitoba, Winnipeg MB, Canada4 aut
7001 a Gearry, Richardu University of Otago, Christchurch, New Zealand4 aut
7001 a Ng, Siew C.u Department of Medicine and Therapeutics, Institute of Digestive Disease, State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China4 aut
7001 a Mantzaris, Gerassimos J.u Evangelismos-PolyCliniki-Ophthalmiatreion Hospital, Athens, Greece4 aut
7001 a Sartor, Balfouru University of North Carolina, Chapel Hill NC, USA4 aut
7001 a Silverberg, Mark S.u Mount Sinai Hospital, Toronto ON, Canada4 aut
7001 a Riddell, Robertu Mount Sinai Hospital, Toronto ON, Canada4 aut
7001 a Koutroubakis, Ioannis E.u University Hospital Heraklion, Crete, Greece4 aut
7001 a O'Morain, Colmu Faculty of Health Sciences Trinity College Dublin, Dublin, Ireland4 aut
7001 a Lakatos, Peter L.u Semmelweis University, Budapest, Hungary4 aut
7001 a McGovern, Dermot P. B.u Widjaja Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai, Medical Center, Los Angeles CA, USA4 aut
7001 a Halfvarson, Jonas,d 1970-u Örebro universitet,Institutionen för medicinska vetenskaper,Department of Gastroenterology, Faculty of Health and Medical Sciences, Örebro University, Örebro, Sweden4 aut0 (Swepub:oru)jshn
7001 a Reinisch, Walteru McMaster University, Hamilton ON, Canada4 aut
7001 a Rogler, Gerhardu University Hospital of Zuürich, Zurich, Switzerland4 aut
7001 a Kruis, Wolfgangu University of Cologne, Koln, Germany4 aut
7001 a Tysk, Curt,d 1949-u Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden4 aut
7001 a Schreiber, Stefanu University Hopital Schleswig Holstein, Kiel, Germany4 aut
7001 a Danese, Silviou Humanitas University, Milan, Italy4 aut
7001 a Sandborn, Williamu UCSD, San Diego CA, USA4 aut
7001 a Griffiths, Anneu Hospital for Sick Children, Toronto ON, Canada4 aut
7001 a Moum, Bjornu Oslo University Hospital and University Oslo, Oslo, Norway4 aut
7001 a Gasche, Christophu Medical University and General Hospital Vienna, Vienna, Austria4 aut
7001 a Pallone, Francescou University of Rome Tor Vergata, Rome, Italy4 aut
7001 a Travis, Simonu Oxford University Hospital, Oxford, UK4 aut
7001 a Panes, Julianu Hospital Clinic de Barcelona, Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain4 aut
7001 a Colombel, Jean-Fredericu Icahn School of Medicine at Mount Sinai, New York, USA4 aut
7001 a Hanauer, Stephenu Northwestern Feinberg School of Medicine, Chicago IL, USA4 aut
7001 a Peyrin-Biroulet, Laurentu Inserm U954 and Centre Hospitaliers Régionaux et Universitaires (CHU) de Nancy, Lorraine University, Nancy, France4 aut
7102 a Dartmouth-Hitchcock Inflammatory Bowel Disease Center, Dartmouth-Hitchcock Medical Center, Lebanon NH, USAb Department of Health Services, Cedars-Sinai Medical Center, Los Angeles CA, USA4 org
7730 t Gutd London, United Kingdom : BMJ Publishing Group Ltdg 67:2, s. 244-254q 67:2<244-254x 0017-5749x 1468-3288
8564 u https://ora.ox.ac.uk/objects/uuid:fc9213c6-6c8b-4fbc-b995-6c04fdeadaf0/download_file?safe_filename=IOIBD%2BConjoint%2BAnalysis%2BManuscript.pdf&file_format=application%2Fpdf&type_of_work=Journal+article
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-53356
8564 8u https://doi.org/10.1136/gutjnl-2016-312648

Hitta via bibliotek

  • Gut (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy